Levoxyl is an anti-thyroid drug owned by King Pharms. It contains the active ingredient levothyroxine sodium and was approved for market use on 25 May, 2001.
The generics of Levoxyl are expected to be released after 02 October, 2023, following the expiration of the last patent US7101569. This patent, titled 'Methods of administering levothyroxine pharmaceutical compositions', defines the unique administration method used by Levoxyl.
Levoxyl is used in administering Levothyroxine, providing relief to patients with thyroid-related conditions. The method involves administering levothyroxine pharmaceutical compositions contained in the drug.
Levoxyl holds a total of three patents, with each contributing to its unique composition and method of treatment. The last of these patents, US7101569, titled 'Methods of administering levothyroxine pharmaceutical compositions' is set to expire on 02 October, 2023. Following this, the Levoxyl generic is anticipated to become available. Below are the details of the patent: